<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02278081</url>
  </required_header>
  <id_info>
    <org_study_id>4225</org_study_id>
    <nct_id>NCT02278081</nct_id>
  </id_info>
  <brief_title>The Relationship Between Gastroesophageal Reflux and Pediatric Rhinitis: Significance of Pale/Blue Colored Turbinate</brief_title>
  <acronym>Pale Turbinate</acronym>
  <official_title>The Relationship Between Gastroesophageal Reflux and Pediatric Rhinitis: Significance of Pale/Blue Colored Turbinate. A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McGill University Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McGill University Health Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gastroesophageal(GERD) reflux disease is a very common problem among pediatric population and
      has be proved to contribute in numerous otolaryngological manifestations. Trails of empirical
      treatment of antireflux medications is often used as a diagnostic test. However, the
      investigators believe GERD can cause rhinitis and nasal obstruction. Nasonex is considered as
      first line treatment for nasal obstruction. Hence, the proposed study aims to define the
      relationship between GERD and rhinitis using randomize control trial where one group of
      patients will receive nasonex and placebo, while the other group will receive nasonex and
      antireflux medications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study is a randomized controlled trial in which children with nasal obstruction
      will be randomized to receive either antireflux medication lansoprazole (prevacid) and
      mometasone furonate (nasonex) or only nasonex and placebo. The diagnosis of nasal obstruction
      will be made by history and physical examination.

      The study will take place at Montreal children's hospital. After the patients or parents of
      the patients agree for their children to take part in the study and sign a consent/assent
      form, baseline information will be collected and the patients will asked to fill out three
      questionnaires for GERD symptoms and nasal symptom. After that eligible patients will undergo
      sinus x-ray, nasal endoscopy and allergy skin test (these test are routine performed for all
      patients with symptoms of nasal obstruction). Then the patients will further be sub-divided
      into two groups based on the allergic skin prick test (SPT); allergy positive and allergy
      negative group. In each group patients will randomly allocated to one of the two study arms;
      group A will receive lansoprazole (prevacid) and mometasone furonate (nasonex) and the other
      group will receive nasonex and placebo. The lansoprazole/placebo will be discontinued after 3
      months and the patients will undergo nasal endoscopy and will be asked to fill out the three
      questionnaires again to assess the improvement. The patients will be follow for another 3
      months, the patients will again undergo nasal endoscopy and will asked to fill out the three
      questionnaires to assess the improvement and sustainability.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>improvement of the nasal signs and symptoms.</measure>
    <time_frame>three months</time_frame>
    <description>after three months of treatment the patient symptoms will be evaluated using subjective questionnaires and nasal endoscopic exam .</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">98</enrollment>
  <condition>Rhinitis</condition>
  <condition>Nasal Obstruction</condition>
  <condition>GERD</condition>
  <arm_group>
    <arm_group_label>treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The treatment group will receive 30 mg lansoprazole (prevacid) one capsule per day for three months and mometasone furonate (nasonex) one puff in each nostril per day for three months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo group will receive one capsule per day of prevacid placebo for three months and mometasone furonate (nasonex) one puff in each nostril per day for three months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lansoprazole</intervention_name>
    <description>the lansoprazole will be taken orally.</description>
    <arm_group_label>treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>the lansoprazole placebo will be taken orally.</description>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  7 (seven) to 17 (seventeen) years of age.

          -  Nasal obstruction as main complaint.

        Exclusion Criteria:

          -  Structural cause of nasal obstruction (deviated nasal septum, adenoid hypertrophy,
             nasal polyps, nasal tumors)

          -  Received antireflux medication during the last three months.

          -  Acute sinusitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>John J Manoukian, MD, FRCSC, FACS</last_name>
    <phone>( 514 ) 412-4400</phone>
    <phone_ext>25302</phone_ext>
    <email>john.manoukian@mcgill.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Abdullah A Alarfaj, MD.</last_name>
    <phone>514 582-3229</phone>
    <email>abdullah.alarfaj@mail.mcgill.ca</email>
  </overall_contact_backup>
  <reference>
    <citation>Vandenplas Y, Rudolph CD, Di Lorenzo C, Hassall E, Liptak G, Mazur L, Sondheimer J, Staiano A, Thomson M, Veereman-Wauters G, Wenzl TG, North American Society for Pediatric Gastroenterology Hepatology and Nutrition, European Society for Pediatric Gastroenterology Hepatology and Nutrition. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr. 2009 Oct;49(4):498-547. doi: 10.1097/MPG.0b013e3181b7f563.</citation>
    <PMID>19745761</PMID>
  </reference>
  <reference>
    <citation>Zalzal GH, Tran LP. Pediatric gastroesophageal reflux and laryngopharyngeal reflux. Otolaryngol Clin North Am. 2000 Feb;33(1):151-61. Review.</citation>
    <PMID>10637349</PMID>
  </reference>
  <reference>
    <citation>Ali Mel-S. Laryngopharyngeal reflux: diagnosis and treatment of a controversial disease. Curr Opin Allergy Clin Immunol. 2008 Feb;8(1):28-33. doi: 10.1097/ACI.0b013e3282f3f44f. Review.</citation>
    <PMID>18188014</PMID>
  </reference>
  <reference>
    <citation>Karkos PD, Leong SC, Apostolidou MT, Apostolidis T. Laryngeal manifestations and pediatric laryngopharyngeal reflux. Am J Otolaryngol. 2006 May-Jun;27(3):200-3. Review.</citation>
    <PMID>16647985</PMID>
  </reference>
  <reference>
    <citation>Al-Saab F, Manoukian JJ, Al-Sabah B, Almot S, Nguyen LH, Tewfik TL, Daniel SJ, Schloss MD, Hamid QA. Linking laryngopharyngeal reflux to otitis media with effusion: pepsinogen study of adenoid tissue and middle ear fluid. J Otolaryngol Head Neck Surg. 2008 Aug;37(4):565-71.</citation>
    <PMID>19128594</PMID>
  </reference>
  <reference>
    <citation>Contencin P, Maurage C, Ployet MJ, Seid AB, Sinaasappel M. Gastroesophageal reflux and ENT disorders in childhood. Int J Pediatr Otorhinolaryngol. 1995 Jun;32 Suppl:S135-44.</citation>
    <PMID>7665283</PMID>
  </reference>
  <reference>
    <citation>El-Serag HB, Gilger M, Kuebeler M, Rabeneck L. Extraesophageal associations of gastroesophageal reflux disease in children without neurologic defects. Gastroenterology. 2001 Dec;121(6):1294-9.</citation>
    <PMID>11729108</PMID>
  </reference>
  <reference>
    <citation>Yüksel F, Doğan M, Karataş D, Yüce S, Şentürk M, Külahli I. Gastroesophageal reflux disease in children with chronic otitis media with effusion. J Craniofac Surg. 2013 Mar;24(2):380-3. doi: 10.1097/SCS.0b013e31827feb08.</citation>
    <PMID>23524698</PMID>
  </reference>
  <reference>
    <citation>Nair S, Kumar M, Nair P. Role of GERD in children with otitis media with effusion. Indian J Pediatr. 2012 Oct;79(10):1328-32. doi: 10.1007/s12098-011-0671-y. Epub 2012 Jan 7.</citation>
    <PMID>22227976</PMID>
  </reference>
  <reference>
    <citation>Benninger MS, Ferguson BJ, Hadley JA, Hamilos DL, Jacobs M, Kennedy DW, Lanza DC, Marple BF, Osguthorpe JD, Stankiewicz JA, Anon J, Denneny J, Emanuel I, Levine H. Adult chronic rhinosinusitis: definitions, diagnosis, epidemiology, and pathophysiology. Otolaryngol Head Neck Surg. 2003 Sep;129(3 Suppl):S1-32. Review.</citation>
    <PMID>12958561</PMID>
  </reference>
  <reference>
    <citation>Phipps CD, Wood WE, Gibson WS, Cochran WJ. Gastroesophageal reflux contributing to chronic sinus disease in children: a prospective analysis. Arch Otolaryngol Head Neck Surg. 2000 Jul;126(7):831-6.</citation>
    <PMID>10888994</PMID>
  </reference>
  <reference>
    <citation>Lupa M, DelGaudio JM. Evidence-based practice: reflux in sinusitis. Otolaryngol Clin North Am. 2012 Oct;45(5):983-92. doi: 10.1016/j.otc.2012.06.004. Epub 2012 Aug 9. Review.</citation>
    <PMID>22980679</PMID>
  </reference>
  <reference>
    <citation>Loehrl TA, Smith TL, Darling RJ, Torrico L, Prieto TE, Shaker R, Toohill RJ, Jaradeh SS. Autonomic dysfunction, vasomotor rhinitis, and extraesophageal manifestations of gastroesophageal reflux. Otolaryngol Head Neck Surg. 2002 Apr;126(4):382-7.</citation>
    <PMID>11997777</PMID>
  </reference>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2014</study_first_submitted>
  <study_first_submitted_qc>October 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2014</study_first_posted>
  <last_update_submitted>October 27, 2014</last_update_submitted>
  <last_update_submitted_qc>October 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McGill University Health Center</investigator_affiliation>
    <investigator_full_name>John Manoukian</investigator_full_name>
    <investigator_title>Associate Professor, Faculty of Medicine, McGill University, Department of Otolaryngology-Head and Neck Surgery</investigator_title>
  </responsible_party>
  <keyword>Rhinitis (nasal obstruction) and GERD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Nasal Obstruction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

